Burzynski Research Institute, Inc. (BZYR)
Develops experimental cancer drugs made from amino acids and peptides.
$0.00+0.12%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-90.6%
The outlook
BZYR is trading near its 52-week low with minimal analyst coverage. The stock sits well below both its 50- and 200-day moving averages, reflecting a sustained downtrend. Current market positioning and available data suggest a weak technical setup.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Market cap
$591,518
52-wk high
$0.05
52-wk low
$0.00
50-day avg
$0.01
200-day avg
$0.02
Trailing P/E
—